Skip to main content

Japan's Yamatake Licenses OGT's Oligo IP to Develop Microarrays

NEW YORK (GenomeWeb News) – Japan’s Yamatake has licensed Oxford Gene Technology’s oligonucleotide microarray patents to make and sell its own arrays, OGT said today.
 
Yamatake will manufacture gemkey microarrays using in situ synthesis. Yamatake is the only Japanese company using in situ synthesis, said Michael Bennett, OGT’s vice president of licensing.
 
The company will market the microarrays through its distributor, Sigma-Aldrich Japan.
 
The license will remain valid for the patents’ lifetime.
 
Yamatake is the second Japanese company this month to license the patents from OGT: Japan’s NGK Insulators signed a similar deal Aug. 1.
 
Financial details were not disclosed.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.